Let life-saving drugs no longer be in short supply-the construction of a centralized production base for the drug consortium ensures the supply of small varieties of drugs

Small-species medicines (shortage medicines) are urgently needed life-saving medicines for some patients.

There is a shortage of life-saving medicines and their prices are high, but they cannot be replaced.

Low profits, small demand, and shortage of medicines for a time when there was no medicine available for patients

Small-species drugs (shortage drugs) refer to drugs that are clinically necessary, small in dosage, unstable in market supply, and prone to clinical shortages.

At the beginning of 2017, due to the lack of raw materials, a large number of penicillamine tablets were discontinued nationwide.

"Hepatolenticular degeneration is an autosomal recessive inherited copper metabolism disorder.

The out-of-stocks and out-of-stocks of the past no longer exist.

“At that time, penicillamine tablets were out of stock and out of stock.

Gu Haoliang said that the causes of the problem of small-species medicines are complex, and the supply problems have been around for a long time.

Actively coordinate the upstream and downstream of the industrial chain, and innovatively establish a drug consortium

In fact, the issue of guaranteeing the supply of small varieties of medicines has long been highly valued by relevant state departments.

On June 27, 2017, the former National Health and Family Planning Commission, the National Development and Reform Commission, the Ministry of Industry and Information Technology and other departments jointly issued the "Implementation Opinions on Reforming and Improving the Supply Guarantee Mechanism for Shortage Drugs.

The "Notice" pointed out that the enterprises that build the concentrated production bases for small-species drugs should be top 100 enterprises in the pharmaceutical industry, with more than 20 small-species drug production numbers and the supporting production capacity of raw materials, and comply with the complete dosage form and quality of the drugs in production (vaccine).

"After inspection and evaluation, the state has recognized that Shanghai Pharmaceuticals Group Co.

The establishment of the consortium and the construction of a centralized production base for small-variety medicines have effectively guaranteed the production and supply of small-variety medicines in my country.

Gu Haoliang believes that in order to solve the problem of supply of small varieties of medicines, the core is to solve the problem of supporting supply of raw materials and other raw materials.

To this end, Shanghai Pharmaceuticals and 26 companies across the country jointly established the country’s first small-species drug (shortage drug) supply guarantee consortium (hereinafter referred to as the "pharmaceutical consortium").

"At the same time, in order to restore the guaranteed supply of medicines, companies start from the needs of patients, increase production and supply, and guarantee medicines for patients.

Gu Haoliang said that in the future, Shanghai Pharmaceuticals will further play the role of the drug consortium platform, and hopes that more companies will join the drug consortium, strengthen communication with the government through the platform, and promote a market-oriented supply guarantee mechanism.
At the same time, we will enrich the range of products guaranteed by the base, strengthen collaboration, and further strengthen the innovative research and development of small-species drugs, so that the drug consortium can exert greater value.

Let more people take assured medicine and low-cost medicine

There are also some rare disease drugs in the small variety of medicines.
In May 2018, the National Health Commission and other five departments jointly issued the "First Batch of Rare Disease Catalog", and 121 rare diseases were included in the catalog.

"At present, Shanghai Pharmaceuticals also regards rare disease drugs as one of the innovative development sectors of the company to ensure supply.
" Gu Haoliang said that Shanghai Pharmaceuticals is the company with the largest number of rare disease drug approvals in China, and the existing products are used to treat rare diseases.
17 varieties, involving 18 indications, "Since the promotion of the rare disease business platform in the second half of 2019, the production of 4 products including tretinoin tablets has been resumed.
"

In January 2019, the list of the construction units of the first batch of small-species drugs (shortage drugs) centralized production bases was released.
The reporter learned that as the country's first batch of centralized production bases for small-species medicines (shortage medicines), Shanghai Pharmaceuticals invested 200 million yuan to build a production base for small-species medicines.
Up to now, the guaranteed supply has reached 32 varieties.

The guarantee of the supply of small-species medicines is a major livelihood issue and a manifestation of the fulfillment of social responsibilities by pharmaceutical manufacturers.
Gu Haoliang believes that the construction of centralized production bases by six key enterprises is the most direct, accurate and effective way to realize the supply of small-species medicines, so as to ensure the supply of shortage medicines from "fire fighting" to normalization and systematization.
"As a representative of national pharmaceutical companies, Shanghai Pharmaceuticals will do everything possible to ensure the supply of medicines in short supply, ensure the quality and safety of medicines, and let more people take assured medicines and low-priced medicines.
" Gu Haoliang said.
(Reporter Zhang Yaxiong)